Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBB 1464 MS tabletDrug: BIBB 1464 MS solutionDrug: BIBB 1464 MS placeboOther: Standard dinner
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 73
- Registration Number
- NCT02229838
Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms
Phase 2
Completed
- Conditions
- Gastrointestinal Diseases
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1637
- Registration Number
- NCT02229786
Safe Implementation of Thrombolysis in Stroke - Monitoring Study
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6475
- Registration Number
- NCT02229812
Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV
Phase 1
Terminated
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02229760
Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 128
- Registration Number
- NCT02229747
Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02226926
Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Liver CirrhosisHepatitis C, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT02226939
Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 35
- Registration Number
- NCT02227017
Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT02226991
Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02226978